Nurix Therapeutics (NRIX) Gains On Bexobrutideg Data As Fair Value Debate Returns

Simply Wall St.11-07

Nurix Therapeutics (NRIX) is back in focus after releasing new Phase 1a/1b data for its BTK degrader bexobrutideg at the 68th American Society of Hematology meeting, highlighting high response rates ...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment